Evidence map›Paper›PMID 36282911›Full record

ArticleScience signaling2022

Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication.

Tomer M Yaron, Brook E Heaton, Tyler M Levy, Jared L Johnson, Tristan X Jordan, Benjamin M Cohen, Alexander Kerelsky, Ting-Yu Lin, Katarina M Liberatore, Danielle K Bulaon and 37 more

Open access · hybridAbstract read
In one paragraph

Article in Science signaling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026
    Review
  11. Review
  12. SARS-CoV-2 S assembly into virions facilitated by host ERM proteins.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 8 institutions in 3 countries.

Tomer M YaronMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-6574-7314
Brook E HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2839-3806
Tyler M LevyCell Signaling Technology, Danvers, MA 01923, USA.ORCID 0000-0003-4634-4063
Jared L JohnsonMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-1802-6527
Tristan X JordanGrossman School of Medicine, New York University, New York, NY 10016, USA.ORCID 0000-0002-0602-2871
Benjamin M CohenMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-6283-2038
Alexander KerelskyMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Ting-Yu LinMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-8335-364X
Katarina M LiberatoreMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Danielle K BulaonEnglander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-8644-3109
Samantha J Van NestDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-1156-5811
Nikos KoundourosMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-8378-9673
Edward R KastenhuberMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Marisa N MercadanteMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Kripa Shobana-GaneshMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-1071-1546
Long HeMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-4721-9221
Robert E SchwartzDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-5417-5995
Shuibing ChenDepartment of Surgery, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0002-6294-5187
Harel WeinsteinEnglander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.
Olivier ElementoEnglander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-8061-9617
Elena PiskounovaMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Benjamin E Nilsson-PayantGrossman School of Medicine, New York University, New York, NY 10016, USA.ORCID 0000-0003-2661-7837
Gina LeeDepartment of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Irvine, CA 92868, USA.ORCID 0000-0002-8120-9169
Joseph D TrimarcoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-5463-7144
Kaitlyn N BurkeDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
Cait E HameleDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-0077-7840
Ryan R ChaparianDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
Alfred T HardingDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1446-2359
Aleksandra TataDepartment of Cell Biology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-3270-0485
Xinyu ZhuDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-1805-7203
Purushothama Rao TataDepartment of Cell Biology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-4837-0337
Clare M SmithDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0003-2601-0955
Anthony P PossematoCell Signaling Technology, Danvers, MA 01923, USA.ORCID 0000-0001-7484-5549
Sasha L TkachevCell Signaling Technology, Danvers, MA 01923, USA.ORCID 0000-0003-3984-8351
Peter V HornbeckCell Signaling Technology, Danvers, MA 01923, USA.ORCID 0000-0002-1126-5149
Sean A BeausoleilCell Signaling Technology, Danvers, MA 01923, USA.ORCID 0000-0002-3356-4641
Shankara K AnandBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-4514-0835
François AguetBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-9414-300X
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-0936-0753
Andrew D DavidsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0002-1136-4008
Kate HeesomProteomics Facility, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0002-5418-5392
Maia Kavanagh-WilliamsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0002-4659-8613
David A MatthewsSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0003-4611-8795
Benjamin R tenOeverGrossman School of Medicine, New York University, New York, NY 10016, USA.ORCID 0000-0003-0324-3078
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-1298-7653
John BlenisMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-3622-2337
Nicholas S HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-5307-3428
Cornell University · USDuke University · USCell Signaling Technology (United States) · USUniversity of Bristol · GBBroad Institute · USNew York University · USHarvard University · USUniversity of California, Irvine · US

Funding

Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
SIGNAL TRANSDUCTION TO PP70 S6KR01GM051405 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN · 1995 to 2023
$14.0M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
Molecular control of a novel transitional cell state in alveolar regenerationR01HL153375 · NHLBI · DUKE UNIVERSITY · PI Purushothama Rao Tata · 2020 to 2026
$3.4M
Mechanisms of submucosal gland cell mediated airway regenerationR01HL146557 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2019 to 2023
$2.0M
NCI NIH HHS T32 CA009111NHLBI NIH HHS R01 HL146557NHLBI NIH HHS R01 HL153375NIAID NIH HHS UC6 AI058607NIGMS NIH HHS R01 GM051405
6 · The paper itself

Abstract

Multiple coronaviruses have emerged independently in the past 20 years that cause lethal human diseases. Although vaccine development targeting these viruses has been accelerated substantially, there remain patients requiring treatment who cannot be vaccinated or who experience breakthrough infections. Understanding the common host factors necessary for the life cycles of coronaviruses may reveal conserved therapeutic targets. Here, we used the known substrate specificities of mammalian protein kinases to deconvolute the sequence of phosphorylation events mediated by three host protein kinase families (SRPK, GSK-3, and CK1) that coordinately phosphorylate a cluster of serine and threonine residues in the viral N protein, which is required for viral replication. We also showed that loss or inhibition of SRPK1/2, which we propose initiates the N protein phosphorylation cascade, compromised the viral replication cycle. Because these phosphorylation sites are highly conserved across coronaviruses, inhibitors of these protein kinases not only may have therapeutic potential against COVID-19 but also may be broadly useful against coronavirus-mediated diseases.

Indexed as

COVID-19SARS-CoV-2AnimalsGlycogen Synthase Kinase 3HumansMammalsNucleocapsidNucleocapsid ProteinsPhosphorylationProtein Serine-Threonine KinasesSerineThreonineVirus ReplicationGlycogen Synthase Kinase 3Nucleocapsid ProteinsProtein Serine-Threonine KinasesSerineSRPK1 protein, humanThreonine

Identifiers

PMID36282911
PMCPMC9830954
OpenAlexW4307380779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.